Natural Capsules Limited has informed the Exchange regarding of 25000 Options.
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natural Capsules Limited's Board meeting on May 27, 2026 approved multiple items including the allotment of 25,000 equity shares (face value Rs.10) against exercise of vested ESOP options at Rs.10 per option, raising Rs.2.5 lakhs. The paid-up capital increased from Rs.10,38,61,540 to Rs.10,41,11,540. For FY2026, standalone revenue grew 3.5% to Rs.17,377 lakhs while net profit jumped 67% to Rs.1,121 lakhs from Rs.671 lakhs in FY2025. Diluted EPS improved significantly from Rs.6.43 to Rs.10.79. The Board also re-appointed Mr. Laxminarayan Moondra as Whole-time Director and appointed new Company Secretary and Internal Auditor. Statutory auditors issued an unmodified opinion on the financial statements.
Strong financial performance with 67% profit growth is positive for shareholders. The ESOP exercise is dilutive but minimal (25,000 shares out of 1.04 crore total). Management changes and clean audit opinion suggest stable governance.